Group Art Unit: 1639 Examiner: B.M. Celsa

REMARKS

Claims 1-18 remain pending in the present application.

Response to Species Election Under 35 U.S.C. §121

The Examiner has required Applicants to elect, under 35 U.S.C. §121, a single disclosed from each of: (A) independent and/or patentably distinct "creatine compounds; and (B) independent and/or patentably distinct "nervous system diseases" (prevention and treatment).

Applicants hereby elect creatine from (A) and Huntington's disease from (B) without traverse.

It is Applicants understanding that the species election is for searching purposes only, and upon a finding of allowability of the elected species, the remaining species also will be searched.

SUMMARY

Cancellation of claims should in no way be construed as an acquiescence to any of the Examiner's objections and/or rejections. The cancellation of claims are being made solely to expedite prosecution of the above-identified application. Applicants reserve the option to further prosecute the same or similar claims in the present or another patent application. The cancellation of the claims are not related to any issues of patentability.

It is respectfully submitted that this application is in condition for allowance. If there are any remaining issues or the Examiner believes that a telephone conference with Applicants' Attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned at (617) 227-7400.

Date: November 14, 2005

LAHIVE & COCKFIELD, LLP

Cynthia M. Soroos

Reg. No. 53,623

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, MA 02109

(617) 227-7400

(617) 742-4214

Attorney/Agent for Applicants